305
J = 2.4 Hz, Ar), 7.66 (d, 2H, J = 8.4 Hz, ArF), 8.61 (s, 1H, HC phenoxyimine ligand (2.0 mmol) in diethyl ether (20 mL) at
= N), 13.34 (s, 1H, ArOH). 19F NMR (376 MHz, CDCl3): –78 ºC. After warming to room temperature, this solution was
δ –70.28 (s).
stirred for 30 min before being added via cannula to a solution
of titanium tetrachloride (1.0 M in toluene, 1.0 mmol) in
diethyl ether (20 mL) at –78 ºC. The resulting solution was
warmed to room temperature and stirred under nitrogen for
12 h. The solvent was removed in vacuo; residues were taken
up in methylene chloride and filtered through Celite to give a
clear dark red solution. The solvent was removed in vacuo,
and the resulting solid was recrystallized from a toluene/
hexane mixture to give the desired complex.
N-(3,5-di-t-butylsalicylidene)-2,6-difluoroaniline
(2,6-F2-PHI)H
3,5-Di-tert-butyl-2-hydroxybenzaldehyde (1.6 g, 6.7 mmol)
and 2,6-difluoroaniline (0.86 g, 6.7 mmol) were reacted to
1
give the desired ligand as yellow crystals (1.78 g, 76%). H
NMR (400 MHz CDCl3): δ 1.33 (s, 9H, tBu), 1.45 (s, 9H, tBu),
6.97 (m, 2H, ArF), 7.10 (m, 1H, ArF), 7.18 (d, 1H, J = 2.4 Hz,
Ar), 7.47 (d, 1H, J = 2.4 Hz, Ar), 8.84 (s, 1H, HC = N), 13.40
(s, 1H, ArOH). 19F NMR (376 MHz, CDCl3): δ 9.14 (t).
(2-F-PHI)2TiCl2 (2)
(2-F-PHI)H (0.85 g, 2.6 mmol) was reacted as described
N-(3,5-di-t-butylsalicylidene)-3,4,5-trifluoroaniline
(3,4,5-F3-PHI)H
above, producing red-brown crystals (0.39 g, 39%). 1H NMR
t
t
(400 MHz, CDCl3): δ 1.26 (s, 18H, Bu), 1.29 (s, 18H, Bu),
6.90 (m, 4H, ArF), 7.08 (d, 2H, J = 2.4 Hz, Ar), 7.30 (m, 4H,
ArF), 7.43 (d, 2H, J = 2.4 Hz, Ar), 8.10 (s, 2H, HC = N).
3,5-Di-tert-butyl-2-hydroxybenzaldehyde (1.6 g, 6.7 mmol)
and 3,4,5-trifluoroaniline (0.98 g, 6.7 mmol) were reacted to
give the desired ligand as orange crystals (2.25 g, 93%).
t
1H NMR (400 MHz, CDCl3): δ 1.31 (s, 9H, Bu), 1.45 (s, 9H,
(4-F-PHI)2TiCl2 (3)
tBu), 6.92 (m, 2H, ArF), 7.21 (d, 1H, J = 2.4 Hz, Ar), 7.48 (d, 1H,
J = 2.4 Hz, Ar), 8.54 (s, 1H, HC = N), 13.02 (s, 1H, ArOH).
19F NMR (376 MHz, CDCl3): δ –30.50 (m), –0.76 (m).
(4-F-PHI)H (0.98 g, 3.0 mmol) was reacted as described
above, producing red-brown crystals (0.51 g, 44%). 1H NMR
(400 MHz, CDCl3, isomeric mixture in solution, 63% C2-
t
t
symmetric isomer): δ 1.25 (s, 18H, Bu), 1.30 (s, 18H, Bu),
N-(3,5-di-t-butylsalicylidene)-3,5-difluoroaniline
(3,5-F2-PHI)H
t
1.31, 1.33, 1.59 (s, Bu, C1 isomer), 7.05 (d, 2H, J = 2.4 Hz,
Ar), 7.08 (d, Ar, C1isomer), 7.12 (d, 4H, J = 7.6 Hz, ArF), 7.27
(d, 4H, J = 8.4 Hz, ArF), 7.46, 7.48 (d, ArF, C1 isomer), 7.49 (d,
2H, J = 2.4 Hz, Ar), 7.62, 7.69 (d, Ar, C1 isomer), 7.92, 8.04 (s,
HC = N, C1 isomer), 8.06 (s, 2H, HC = N).
3,5-Di-tert-butyl-2-hydroxybenzaldehyde (1.7 g, 7.2 mmol)
and 3,5-difluoroaniline (0.92 g, 7.2 mmol) were reacted to
give the desired ligand as yellow-brown crystals (1.99 g,
80%). 1H NMR (400 MHz, CDCl3): δ 1.31 (s, 9H, tBu), 1.46 (s,
9H, tBu), 6.71 (m, 1H, ArF), 6.80 (m, 2H, ArF), 7.22 (d, 1H, J =
2.4 Hz, Ar), 7.48 (d, 1H, J = 2.4 Hz, Ar), 8.60 (s, 1H, HC = N),
13.14 (s, 1H, ArOH). 19F NMR (376 MHz, CDCl3): δ –23.40 (t).
(4-CF3-PHI)2TiCl2 (4)
(4-CF3-PHI)H (1.16 g, 3.1 mmol) was reacted as described
1
above, producing dark red crystals (0.94 g, 70%). H NMR
(400 MHz, CDCl3, isomeric mixture in solution, 63% C2-
N-(3,5-di-t-butylsalicylidene)-3,5-bis(trifluoromethyl)aniline
(3,5-CF3-PHI)H
t
t
symmetric isomer): δ 1.24 (s, 18H, Bu), 1.30 (s, 18H, Bu),
t
1.31, 1.32, 1.34, 1.59 (s, Bu, C1 isomer), 6.80 (d, ArF, C1
3,5-Di-tert-butyl-2-hydroxybenzaldehyde (1.6 g, 6.7 mmol)
and 3,5-bis(trifluoromethyl)aniline (1.5 g, 6.7 mmol) were dis-
solved in methanol (20 mL) and heated at reflux for 12 h.
Concentration of the solvent and crystallization at –20 ºC
produced the desired ligand as orange crystals (1.98 g, 64%).
isomer), 7.06 (d, 2H, J = 2.4 Hz, Ar), 7.08 (d, Ar, C1 isomer),
7.12 (d, 4H, J = 8.0 Hz, ArF), 7.27 (d, 4H, J = 8.0 Hz, ArF),
7.45, 7.47 (d, ArF, C1 isomer), 7.49 (d, 2H, J = 2.4 Hz, Ar),
7.63, 7.69 (d, Ar, C1 isomer), 7.91, 8.04 (s, HC = N, C1
isomer), 8.07 (s, 2H, HC = N).
t
1H NMR (400 MHz, CDCl3): δ 1.33 (s, 9H, Bu), 1.44 (s, 9H,
tBu), 7.27 (m, 1H, ArF), 7.52 (d, 1H, J = 2.4 Hz, Ar), 7.68 (m, 2H,
ArF), 7.77 (d, 1H, J = 2.4 Hz, Ar), 8.64 (s, 1H, HC = N), 13.28 (s,
1H, ArOH). 19F NMR (376 MHz, CDCl3): δ –69.50 (s).
(2,6-F2-PHI)2TiCl2 (5)
(2,6-F2-PHI)H (0.96 g, 2.8 mmol) was reacted as described
above, producing red-brown crystals (0.72 g, 64%). 1H NMR
t
t
(400 MHz, CDCl3): δ 1.26 (s, 18H, Bu), 1.30 (s, 18H, Bu),
6.43 (m, 2H, ArF), 6.87 (m, 2H, ArF), 6.95 (m, 2H, ArF), 7.15
(d, 2H, J = 2.4 Hz, Ar), 7.51 (d, 2H, J = 2.4 Hz, Ar), 8.19 (s,
2H, HC = N).
N-(3,5-di-t-butylsalicylidene)-2,4,6-trifluoroaniline
(2,4,6-F3-PHI)H
3,5-Di-tert-butyl-2-hydroxybenzaldehyde (1.4 g, 5.9 mmol)
and 2,4,6-trifluoroaniline (0.87 g, 5.9 mmol) were reacted to
give the desired ligand as yellow crystals (1.42 g, 66%).
(3,4,5-F3-PHI)2TiCl2 (6)
t
1H NMR (400 MHz, CDCl3): δ 1.31 (s, 9H, Bu), 1.45 (s, 9H,
(3,4,5-F3-PHI)H (1.13 g, 3.1 mmol) was reacted as described
tBu), 6.76 (m, 2H, ArF), 7.16 (d, 1H, J = 2.4 Hz, Ar), 7.47 (d, 1H,
J = 2.4 Hz, Ar), 8.81 (s, 1H, HC = N), 13.17 (s, 1H, ArOH).
19F NMR (376 MHz, CDCl3): δ –12.63 (t), 8.72 (m).
1
above, producing red-brown crystals (0.54 g, 41%). H NMR
(400 MHz, CDCl3, isomeric mixture in solution, 61% C2-sym-
t
t
metric isomer): δ 1.27 (s, 18H, Bu), 1.30, 1.31 (s, Bu, C1
isomer), 1.38 (s, 18H, tBu), 1.58 (s, tBu, C1 isomer), 6.39 (m, ArF,
C1 isomer), 6.62 (m, 4H, ArF), 6.72 (m, ArF, C1 isomer), 7.11 (d,
2H, J = 2.4 Hz, Ar), 7.22 (d, Ar, C1 isomer), 7.58 (d, 2H, J = 2.4
Complex Synthesis
General Procedure for Titanium Complex Synthesis
A gastight syringe was used to dropwise add n-butyl- Hz, Ar), 7.64, 7.70 (d, Ar, C1 isomer), 8.00, 8.01 (s, HC = N, C1
lithium (1.6 M in hexanes, 2.1 mmol) to a stirred solution of isomer), 8.07 (s, 2H, HC = N).
Mason et al. / Effect of Fluorination on Propylene Polymerization